Targeting protein kinases in the malaria parasite: Update of an antimalarial drug target

Current Topics in Medicinal Chemistry

Volumn 12, Issue 5, 2012, Pages 456-472

  Zhang, Veronica M ^a,b   Chavchich, Marina ^a,b   Waters, Norman C ^a,b,c  

^a AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNITED STATES MILITARY ACADEMY   (United States)

Author keywords

Antimalarial agents; Drug development; Kinase family; Plasmodiual protein kinases; Plasmodium falciparum; Protein kinases

Indexed keywords

ANTIMALARIAL AGENT; AURORA KINASE INHIBITOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 7; GLYCOGEN SYNTHASE KINASE 3; MALARIA VACCINE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR;

AMINO ACID SEQUENCE; ANOPHELES; ANTIMALARIAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE; DNA REPLICATION; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; IC 50; MALARIA; MITOSIS; NONHUMAN; PLASMODIUM FALCIPARUM; PROTEIN TARGETING; REVIEW;

ANTIMALARIALS; DRUG DISCOVERY; HUMANS; PLASMODIUM; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 84857774169     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612799362922     Document Type: Review

References (179)

1. Breman, J.G.; Holloway, C.N. Malaria surveillance counts. Am. J. Trop. Med. Hyg., 2007, 77(6 Suppl), 36-47.
2. Arnot, D.E.; Gull, K. The Plasmodium cell-cycle: facts and questions. Ann. of Trop. Med. Parasitol., 1998, 92(4), 361-365.
3. Dixon, M.W.A.; Thompson, J.; Gardiner, D.L.; Trenholme, K.R. Sex in Plasmodium: a sign of commitment. Trends Parasitol., 2008, 24(4), 168-175.
4. Organisation, W.H. (2010) World Malaria Report: 2010.
5. Noedl, H.; Se, Y.; Sriwichai, S.; Schaecher, K.; Teja-Isavadharm, P.; Smith, B.; Rutvisuttinunt, W.; Bethell, D.; Surasri, S.; Fukuda, M.M.; Socheat, D.; Chan Thap, L. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin. Infect. Dis., 2010, 51(11), e82-89.
6. Petersen, I.; Eastman, R.; Lanzer, M. Drug-resistant malaria: molecular mechanisms and implications for public health. FEBS Lett., 2011, 585(11), 1551-1562.
7. Ridley, R.G. Plasmodium: drug discovery and development-an industrial perspective. Exp. Parasitol., 1997, 87(3), 293-304.
8. Jirage, D.; Keenan, S.M.; Waters, N.C. Exploring novel targets for antimalarial drug discovery: plasmodial protein kinases. Infect. Disord. Drug Targets, 2010, 10(3), 134-146.
9. Doerig, C.; Billker, O.; Haystead, T.; Sharma, P.; Tobin, A.B.; Waters, N.C. Protein kinases of malaria parasites: an update. Trends Parasitol., 2008, 24(12), 570-577.
10. Ward, P.; Equinet, L.; Packer, J.; Doerig, C. Protein kinases of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryote. BMC Genomics, 2004, 5(79).
11. Cohen, P. Protein kinases--the major drug targets of the twentyfirst century? Nat. Rev. Drug Discov., 2002, 1(4), 309-315.
12. Anamika; Srinivasan, N.; Krupa, A. A genomic perspective of protein kinases in Plasmodium falciparum. Proteins, 2005, 58(1), 180-189.
13. Doerig, C.; Abdi, A.; Bland, N.; Eschenlauer, S.; Dorin-Semblat, D.; Fennell, C.; Halbert, J.; Holland, Z.; Nivez, M.P.; Semblat, J.P.; Sicard, A.; Reininger, L. Malaria: targeting parasite and host cell kinomes. Biochim. Biophys. Acta., 2010, 1804(3), 604-612.
14. Dorin, D.; Semblat, J.P.; Poullet, P.; Alano, P.; Goldring, J.P.; Whittle, C.; Patterson, S.; Chakrabarti, D.; Doerig, C. PfPK7, an atypical MEK-related protein kinase, reflects the absence of classical three-component MAPK pathways in the human malaria parasite Plasmodium falciparum. Mol. Microbiol., 2005, 55(1), 184-196.
15. Kozlov, S.; Waters, N.C.; Chavchich, M. Leveraging cell cycle analysis in anticancer drug discovery to identify novel plasmodial drug targets. Infect. Disord. Drug Targets, 2010, 10(3), 165-190.
16. Wu, T.; Nagle, A.S.; Chatterjee, A.K. Road towards new antimalarials -overview of the strategies and their chemical progress. Curr. Med. Chem., 2011, 18(6), 853-871.
17. Keller, T.H.; Shi, P.Y.; Wang, Q.Y. Anti-infectives: Can cellular screening deliver? Curr. Opin. Chem. Biol., 2011, 15(4), 529-533.
18. Gujjar, R.; El Mazouni, F.; White, K.L.; White, J.; Creason, S.; Shackleford, D.M.; Deng, X.; Charman, W.N.; Bathurst, I.; Burrows, J.; Floyd, D.M.; Matthews, D.; Buckner, F.S.; Charman, S.A.; Phillips, M.A.; Rathod, P.K. Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J. Med. Chem., 2011, 54(11), 3935-3949.
19. Coteron, J.M.; Catterick, D.; Castro, J.; Chaparro, M.J.; Diaz, B.; Fernandez, E.; Ferrer, S.; Gamo, F.J.; Gordo, M.; Gut, J.; de las Heras, L.; Legac, J.; Marco, M.; Miguel, J.; Munoz, V.; Porras, E.; de la Rosa, J.C.; Ruiz, J.R.; Sandoval, E.; Ventosa, P.; Rosenthal, P.J.; Fiandor, J.M. Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series. J. Med. Chem., 2010, 53(16), 6129-6152.
20. Gamo, F.J.; Sanz, L.M.; Vidal, J.; de Cozar, C.; Alvarez, E.; Lavandera, J.L.; Vanderwall, D.E.; Green, D.V.; Kumar, V.; Hasan, S.; Brown, J.R.; Peishoff, C.E.; Cardon, L.R.; Garcia-Bustos, J.F. Thousands of chemical starting points for antimalarial lead identification. Nature, 2010, 465(7296), 305-310.
21. Leroy, D.; Doerig, C. Drugging the Plasmodium kinome: the benefits of academia-industry synergy. Trends Pharmacol. Sci., 2008, 29(5), 241-249.
22. Fischer, P.M. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Curr. Med. Chem., 2004, 11(12), 1563-1583.
23. Fabian, M.A.; Biggs, W.H.; Treiber, D.K.; Atteridge, C.E.; Azimioara, M.D.; Benedetti, M.G.; Carter, T.A.; Ciceri, P.; Edeen, P.T.; Floyd, M.; Ford, J.M.; Galvin, M.; Gerlach, J.L.; Grotzfeld, R.M.; Herrgard, S.; Insko, D.E.; Insko, M.A.; Lai, A.G.; Lelias, J.M.; Mehta, S.A.; Milanov, Z.V.; Velasco, A.M.; Wodicka, L.M.; Patel, H.K.; Zarrinkar, P.P.; Lockhart, D.J. A small moleculekinase interaction map for clinical kinase inhibitors. Nat. Biotechnol., 2005, 23(3), 329-336.
24. Bain, J.; Plater, L.; Elliott, M.; Shpiro, N.; Hastie, J.; McLauchlan, H.; Klevernic, I.; Arthur, S.; Alessi, D.; Cohen, P. The selectivity of protein kinase inhibitors; a further update. Biochem. J., 2007, 408(3), 297-315.
25. Fedorov, O.; Marsden, B.; Pogacic, V.; Rellos, P.; Muller, S.; Bullock, A.N.; Schwaller, J.; Sundstrom, M.; Knapp, S. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA, 2007, 104(51), 20523-20528.
26. Karaman, M.W.; Herrgard, S.; Treiber, D.K.; Gallant, P.; Atteridge, C.E.; Campbell, B.T.; Chan, K.W.; Ciceri, P.; Davis, M.I.; Edeen, P.T.; Faraoni, R.; Floyd, M.; Hunt, J.P.; Lockhart, D.J.; Milanov, Z.V.; Morrison, M.J.; Pallares, G.; Patel, H.K.; Pritchard, S.; Wodicka, L.M.; Zarrinkar, P.P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol., 2008, 26(1), 127-132.
27. Fabbro, D.; Ruetz, S.; Buchdunger, E.; Cowan-Jacob, S.W.; Fendrich, G.; Liebetanz, J.; Mestan, J.; O'Reilly, T.; Traxler, P.; Chaudhuri, B.; Fretz, H.; Zimmermann, J.; Meyer, T.; Caravatti, G.; Furet, P.; Manley, P.W. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther., 2002, 93(2-3), 79-98.
28. Krug, M.; Hilgeroth, A. Recent advances in the development of multi-kinase inhibitors. Mini Rev. Med. Chem., 2008, 8(13), 1312-1327.
29. Kung, C.; Kenski, D.M.; Krukenberg, K.; Madhani, H.D.; Shokat, K.M. Selective kinase inhibition by exploiting differential pathway sensitivity. Chem. Biol., 2006, 13(4), 399-407.
30. Johnson, L.N.; Noble, M.E.; Owen, D.J. Active and inactive protein kinases: structural basis for regulation. Cell, 1996, 85(2), 149-158.
31. Eglen, R.; Reisine, T. Drug discovery and the human kinome: recent trends. Pharmacol. Ther., 2011, 130(2), 144-156.
32. Comess, K.M.; Sun, C.; Abad-Zapatero, C.; Goedken, E.R.; Gum, R.J.; Borhani, D.W.; Argiriadi, M.; Groebe, D.R.; Jia, Y.; Clampit, J.E.; Haasch, D.L.; Smith, H.T.; Wang, S.; Song, D.; Coen, M.L.; Cloutier, T.E.; Tang, H.; Cheng, X.; Quinn, C.; Liu, B.; Xin, Z.; Liu, G.; Fry, E.H.; Stoll, V.; Ng, T.I.; Banach, D.; Marcotte, D.; Burns, D.J.; Calderwood, D.J.; Hajduk, P.J. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. ACS Chem. Biol., 6(3), 234-244.
33. Merckx, A.; Echalier, A.; Langford, K.; Sicard, A.; Langsley, G.; Joore, J.; Doerig, C.; Noble, M.; Enclicott, J. Structures of P. falciparum protein kinase 7 identify an activation motif and leads for inhibitor design. Structure, 2008, 16(2), 228-238.
34. Holton, S.; Merckx, A.; Burgess, D.; Doerig, C.; Noble, M.; Endicott, J. Structures of P. falciparum PfPK5 test the CDKregulation paradigm and suggest mechanisms of small molecule inhibition. Structure, 2003, 11(11), 1329-1337.
35. Arnot DER.E., Bengtsson DC. The progression of the intraerythrocytic cell cycle of Plasmodium falciparum and the role of the centriolar plaques in asynchronous mitotic division during schizogony. Int. J. Parasitol., 2011, 41(1), 71-80.
36. Doerig, C., Chakrabarti, D., Kappes, B., Matthews, K. The cell cycle in protozoan parasites. Prog. Cell Cycle Res., 2000, 4,163-183.
37. Morgan, D.O. Principles of CDK regulation. Nature, 1995, 374(6518), 131-134.
38. Reininger, L.; Wilkes, J.M.; Bourgade, H.; Miranda-Saavedra, D.; Doerig, C. An essential Aurora-related kinase transiently associates with spindle pole bodies during Plasmodium falciparum erythrocytic schizogony. Mol. Microbiol., 2011, 79(1), 205-221.
39. Gerald, N.; Mahajan, B.; Kumar, S. Mitosis in the human malaria parasite Plasmodium falciparum. Eukaryot. Cell, 2011, 10(4), 474-482.
40. Li, J.L.; Robson, K.J.H.; Chen, J.L.; Targett, G.A.T.; Baker, D.A. Pfmrk, a MO15-related protein kinase from Plasmodium falciparum. Gene cloning, sequence, stage-specific expression and chromosome localization. Eur. J. Biochem., 1996, 241(3), 805-813.
41. Rossignol, M.; KolbCheynel, I.; Egly, J.M. Substrate specificity of the cdk-activating kinase (CAK) is altered upon association with TFIIH. EMBO J., 1997, 16(7), 1628-1637.
42. Adamczewski, J.P.; Rossignol, M.; Tassan, J.P.; Nigg, E.A.; Moncollin, V.; Egly, J.M. MAT1, CDK7 and cyclin H form a kinase complex which is UV light-sensitive upon association with TFIIH. EMBO J., 1996, 15(8), 1877-1884.
43. Yankulov, K.Y.; Bentley, D.L. Regulation of CDK7 substrate specificity by MAT1 and TFIIH. EMBO J., 1997, 16(7), 1638-1646.
44. Larochelle, S.; Chen, J.; Knights, R.; Pandur, J.; Morcillo, P.; Erdjument-Bromage, H.; Tempst, P.; Suter, B.; Fisher, R.P. T-loop phosphorylation stabilizes the CDK7-cyclin H-MAT1 complex in vivo and regulates its CTD kinase activity. EMBO J., 2001, 20(14), 3749-3759.
45. Fisher, R.P.; Jin, P.; Chamberlin, H.M.; Morgan, D.O. Atlernative mechanisms of CAK assembly require an assembly factor or an activating kinase. Cell, 1995, 83(1), 47-57.
46. Martinez, A.M.; Afshar, M.; Martin, F.; Cavadore, J.C.; Labbe, J.C.; Doree, M. Dual phosphorylation of the T-loop in CDK7: its role in controlling cyclin H binding and CAK activity. EMBO J., 1997, 16(2), 343-354.
47. Devault, A.; Martinez, A.M.; Fesquet, D.; Labbe, J.C.; Morin, N.; Tassan, J.P.; Nigg, E.A.; Cavadore, J.C.; Doree, M. MAT1 ('menage à trois') a new RING finger protein subunit stabilizing cyclin H-cdk7 complexes in starfish and Xenopus CAK. EMBO J., 1995, 14(20), 5027-5036.
48. Tassan, J.P.; Jaquenoud, M.; Fry, A.M.; Frutiger, S.; Hughes, G.J.; Nigg, E.A. In vitro assembly of a functional human CDK7-cyclin H complex requires MAT1, a novel 36 kDa RING finger protein. EMBO J., 1995, 14(22), 5608-5617.
49. Chen, Y.; Jirage, D.; Caridha, D.; Kathcart, A.K.; Cortes, E.A.; Dennull, R.A.; Geyer, J.A.; Prigge, S.T.; Waters, N.C. Identification of an effector protein and gain-of-function mutants that activate Pfmrk, a malarial cyclin-dependent protein kinase. Mol. Biochem. Parasitol., 2006, 149(1), 48-57.
50. Le Roch, K.; Sestier, C.; Dorin, D.; Waters, N.; Kappes, B.; Chakrabarti, D.; Meijer, L.; Doerig, C. Activation of a Plasmodium falciparum cdc2-related kinase by heterologous p25 and cyclin H. Functional characterization of a P. falciparum cyclin homologue. J. Biol. Chem., 2000, 275(12), 8952-8958.
51. Waters, N.C.; Woodard, C.L.; Prigge, S.T. Cyclin H activation and drug susceptibility of the Pfmrk cyclin dependent protein kinase from Plasmodium falciparum. Mol. Biochem. Parasitol., 2000, 107(1), 45-55.
52. Jirage, D.; Chen, Y.Q.; Caridha, D.; O'Neil, M.T.; Eyase, F.; Witola, W.H.; Ben Mamoun, C.; Waters, N.C. The malarial CDK Pfmrk and its effector PfMAT1 phosphorylate DNA replication proteins and co-localize in the nucleus. Mol. Biochem. Parasitol., 2010, 172(1), 9-18.
53. Keenan, S.M.; Geyer, J.A.; Welsh, W.J.; Prigge, S.T.; Waters, N.C. Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin dependent kinase inhibitors. Comb. Chem. High Throughput Screen, 2005, 8(1), 27-38.
54. Woodard, C.L.; Li, Z.Y.; Kathcart, A.K.; Terrell, J.; Gerena, L.; Lopez-Sanchez, M.; Kyle, D.E.; Bhattacharjee, A.K.; Nichols, D.A.; Ellis, W.; Prigge, S.T.; Geyer, J.A.; Waters, N.C. Oxindolebased compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases. J. Med. Chem., 2003, 46(18), 3877-3882.
55. Woodard, C.L.; Keenan, S.M.; Gerena, L.; Welsh, W.J.; Geyer, J.A.; Waters, N.C. Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk. Bioorg. Med. Chem. Lett., 2007, 17(17), 4961-4966.
56. Xiao, Z.L.; Waters, N.C.; Woodard, C.L.; Li, Z.Y.; Li, P.K. Design and synthesis of Pfmrk inhibitors as potential antimalarial agents. Bioorg. Med. Chem. Lett., 2001, 11(21), 2875-2878.
57. Caridha, D.; Kathcart, A.K.; Jirage, D.; Waters, N.C. Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases. Bioorg. Med. Chem. Lett., 2010, 20(13), 3863-3867.
58. Faidallah, H.M.; Al-Saadi, M.S.; Rostom, S.A.F.; Fahmy, H.T.Y. Synthesis of some sulfonamides, disubstituted sulfonylureas or thioureas and some structurally related variants. A class of promising antitumor agents. Med. Chem. Res., 2007, 16(6), 300-318.
59. Owa, T.; Yokoi, A.; Yamazaki, K.; Yoshimatsu, K.; Yamori, T.; Nagasu, T. Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide. J. Med. Chem., 2002, 45(22), 4913-4922.
60. Yoshimatsu, K.; Yamaguchi, A.; Yoshino, H.; Koyanagi, N.; Kitoh, K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res., 1997, 57(15), 3208-3213.
61. Owa, T.; Yoshino, H.; Okauchi, T.; Yoshimatsu, K.; Ozawa, Y.; Sugi, N.H.; Nagasu, T.; Koyanagi, N.; Kitoh, K. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J. Med. Chem., 1999, 42(19), 3789-3799.
62. Ross-Macdonald, P.B.; Graeser, R.; Kappes, B.; Franklin, R.; Williamson, D.H. Isolation and expression of a gene specifying a cdc2-like protein kinase from the human malaria parasite Plasmodium falciparum. Eur. J. Biochem., 1994, 220(3), 693-701.
63. Graeser, R.; Wernli, B.; Franklin, R.M.; Kappes, B. Plasmodium falciparum protein kinase 5 and the malarial nuclear division cycles. Mol. Biochem. Parasitol., 1996, 82(1), 37-49.
64. Graeser, R.; Franklin, R.M.; Kappes, B. Mechanisms of activation of the cdc2-related kinase PfPK5 from Plasmodium falciparum. Mol. Biochem. Parasitol., 1996, 79(1), 125-127.
65. Harmse, L.; van Zyl, R.; Gray, N.; Schultz, P.; Leclerc, S.; Meijer, L.; Doerig, C.; Havlik, I. Structure-activity relationships and inhibitory effects of various purine derivatives on the in vitro growth of Plasmodium falciparum. Biochem. Pharmacol., 2001, 62(3), 341-348.
66. Merckx, A.; Le Roch, K.; Nivez, M.P.; Dorin, D.; Alano, P.; Gutierrez, G.J.; Nebreda, A.R.; Goldring, D.; Whittle, C.; Patterson, S.; Chakrabarti, D.; Doerig, C. Identification and initial characterization of three novel cyclin-related proteins of the human malaria parasite Plasmodium falciparum. J. Biol. Chem., 2003, 278(41), 39839-39850.
67. Bracchi-Ricard, V.; Barik, S.; DelVecchio, C.; Doerig, C.; Chakrabarti, R.; Chakrabarti, D. PfPK6, a novel cyclin-dependent kinase/mitogen-activated protein kinase-related protein kinase from Plasmodium falciparum. Biochem. J., 2000, 347(255-263.
68. Oakley, B.R.; Morris, N.R. A mutation in Aspergillus nidulans that blocks the transition from interphase to prophase. J. Cell Biol., 1983, 96(4), 1155-1158.
69. O'Connell, M.J.; Krien, M.J.; Hunter, T. Never say never. The NIMA-related protein kinases in mitotic control. Trends Cell Biol., 2003, 13(5), 221-228.
70. Chen, Y.; Chen, P.L.; Chen, C.F.; Jiang, X.; Riley, D.J. Never-inmitosis related kinase 1 functions in DNA damage response and checkpoint control. Cell Cycle, 2008, 7(20), 3194-3201.
71. Dorin, D.; Le Roch, K.; Sallicandro, P.; Alano, P.; Parzy, D.; Poullet, P.; Meijer, L.; Doerig, C. Pfnek-1, a NIMA-related kinasefrom the human malaria parasite Plasmodium falciparum Biochemical properties and possible involvement in MAPK regulation. Eur. J. Biochem., 2001, 268(9), 2600-2608.
72. Schultz, S.J.; Fry, A.M.; Sutterlin, C.; Ried, T.; Nigg, E.A. Cell cycle-dependent expression of Nek2, a novel human protein kinase related to the NIMA mitotic regulator of Aspergillus nidulans. Cell Growth Differ., 1994, 5(6), 625-635.
73. Reininger, L.; Billker, O.; Tewari, R.; Mukhopadhyay, A.; Fennell, C.; Dorin-Semblat, D.; Doerig, C.; Goldring, D.; Harmse, L.; Ranford-Cartwright, L.; Packer, J. A NIMA-related protein kinase is essential for completion of the sexual cycle of malaria parasites. J. Biol. Chem., 2005, 280(36), 31957-31964.
74. Dorin-Semblat, D.; Schmitt, S.; Semblat, J.P.; Sicard, A.; Reininger, L.; Goldring, D.; Patterson, S.; Quashie, N.; Chakrabarti, D.; Meijer, L.; Doerig, C. Plasmodium falciparum NIMA-related kinase Pfnek-1: sex-specificity and assessment of essentiality for the erythrocytic asexual cycle. Microbiology, 2011, 157(Pt 10),2785-2794
75. Lye, Y.M.; Chan, M.; Sim, T.S. Pfnek3: an atypical activator of a MAP kinase in Plasmodium falciparum. FEBS Lett., 2006, 580(26), 6083-6092.
76. Le Roch, K.G.; Zhou, Y.Y.; Blair, P.L.; Grainger, M.; Moch, J.K.; Haynes, J.D.; De la Vega, P.; Holder, A.A.; Batalov, S.; Carucci, D.J.; Winzeler, E.A. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science, 2003, 301(5639), 1503-1508.
77. Laurent, D.; Jullian, V.; Parenty, A.; Knibiehler, M.; Dorin, D.; Schmitt, S.; Lozach, O.; Lebouvier, N.; Frostin, M.; Alby, F.; Maurel, S.; Doerig, C.; Meijer, L.; Sauvain, M. Antimalarial potential of xestoquinone, a protein kinase inhibitor isolated from a Vanuatu marine sponge Xestospongia sp. Bioorg. Med. Chem. Lett., 2006, 14(13), 4477-4482.
78. Desoubzdanne, D.; Marcourt, L.; Raux, R.; Chevalley, S.; Dorin, D.; Doerig, C.; Valentin, A.; Ausseil, F.; Debitus, C. Alisiaquinones and alisiaquinol, dual inhibitors of Plasmodium falciparum enzyme targets from a New Caledonian deep water sponge. J. Nat. Prod., 2008, 71(7), 1189-1192.
79. Lebouvier, N.; Jullian, V.; Desvignes, I.; Maurel, S.; Parenty, A.; Dorin-Semblat, D.; Doerig, C.; Sauvain, M.; Laurent, D. Antiplasmodial activities of homogentisic acid derivative protein kinase inhibitors isolated from a Vanuatu marine sponge Pseudoceratina sp. Mar. Drugs, 2009, 7(4), 640-653.
80. Reininger, L.; Tewari, R.; Fennell, C.; Holland, Z.; Goldring, D.; Ranford-Cartwright, L.; Billker, O.; Doerig, C. An essential role for the Plasmodium Nek-2 Nima-related protein kinase in the sexual development of malaria parasites. J. Biol. Chem., 2009, 284(31), 20858-20868.
81. + signals in plants. Annu. Rev. Plant Biol., 2004, 55, 401-427.
82. Sanders, D.; Pelloux, J.; Brownlee, C.; Harper, J.F. Calcium at the crossroads of signaling. Plant Cell, 2002, 14, S401-S417.
83. Kato, N.; Sakata, T.; Breton, G.; Le Roch, K.G.; Nagle, A.; Andersen, C.; Bursulaya, B.; Henson, K.; Johnson, J.; Kumar, K.A.; Marr, F.; Mason, D.; McNamara, C.; Plouffe, D.; Ramachandran, V.; Spooner, M.; Tuntland, T.; Zhou, Y.; Peters, E.C.; Chatterjee, A.; Schultz, P.G.; Ward, G.E.; Gray, N.; Harper, J.; Winzeler, E.A. Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility. Nat. Chem. Biol., 2008, 4(6), 347-356.
84. Billker, O.; Dechamps, S.; Tewari, R.; Wenig, G.; Franke-Fayard, B.; Brinkmann, V. Calcium and a calcium-dependent protein kinase regulate gamete formation and mosquito transmission in a malaria parasite. Cell, 2004, 117(4), 503-514.
85. Green, J.L.; Rees-Channer, R.R.; Howell, S.A.; Martin, S.R.; Knuepfer, E.; Taylor, H.M.; Grainger, M.; Holder, A.A. The motor complex of Plasmodium falciparum: phosphorylation by a calciumdependent protein kinase. J. Biol. Chem., 2008, 283(45), 30980-30989.
86. Coppi, A.; Tewari, R.; Bishop, J.R.; Bennett, B.L.; Lawrence, R.; Esko, J.D.; Billker, O.; Sinnis, P. Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells. Cell Host Microbe, 2007, 2(5), 316-327.
87. Ishino, T.; Orito, Y.; Chinzei, Y.; Yuda, M. A calcium-dependent protein kinase regulates Plasmodium ookinete access to the midgut epithelial cell. Mol. Microbiol., 2006, 59(4), 1175-1184.
88. Farber, P.M.; Graeser, R.; Franklin, R.M.; Kappes, B. Molecular cloning and characterization of a second calcium-dependent protein kinase of Plasmodium falciparum. Mol. Biochem. Parasitol., 1997, 87(2), 211-216.
89. Harper, J.F.; Harmon, A. Plants, symbiosis and parasites: a calcium signalling connection. Nat. Rev. Mol. Cell Biol., 2005, 6(7), 555-566.
90. Li, J.L.; Baker, D.A.; Cox, L.S. Sexual stage-specific expression of a third calcium-dependent protein kinase from Plasmodium falciparum. Biochim. Biophys. Acta., 2000, 1491(1-3), 341-349.
91. Zhao, Y., Kappes, B., Franklin, R.M. Gene structure and expression of an unusual protein kinase from Plasmodium falciparum homologus at its carboxy terminus with the EF hand calcium-binding proteins. J. Biol. Chem., 1993, 268(6), 4347-4354.
92. Harper, J.F.; Binder, B.M.; Sussman, M.R. Calcium and lipid regulation of an Arabidopsis protein kinase expressed in Escherichia coli. Biochemistry, 1993, 32(13), 3282-3290.
93. Harmon, A.C.; Yoo, B.C.; McCaffery, C. Pseudosubstrate inhibition of CDPK, a protein kinase with a calmodulin-like domain. Biochemistry, 1994, 33(23), 7278-7287.
94. Bozdech, Z.; Llinas, M.; Pulliam, B.L.; Wong, E.D.; Zhu, J.C.; DeRisi, J.L. The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol., 2003, 1(1), 85-100.
95. Siden-Kiamos, I.; Ecker, A.; Nyback, S.; Louis, C.; Sinden, R.E.; Billker, O. Plasmodium berghei calcium-dependent protein kinase 3 is required for ookinete gliding motility and mosquito midgut invasion. Mol. Microbiol., 2006, 60(6), 1355-1363.
96. Silva-Neto, M.A.C.; Atella, G.C.; Shahabuddin, M. Inhibition of Ca2+/calmodulin-dependent protein kinase blocks morphological differentiation of Plasmodium gallinaceum zygotes to ookinetes. J. Biol. Chem., 2002, 277(16), 14085-14091.
97. Ranjan, R.; Ahmed, A.; Gourinath, S.; Sharma, P. Dissection of mechanisms involved in the regulation of Plasmodium falciparum calcium-dependent protein kinase 4. J. Biol. Chem., 2009, 284(22), 15267-15276.
98. Moskes, C.; Burghaus, P.A.; Wernli, B.; Sauder, U.; Durrenberger, M.; Kappes, B. Export of Plasmodium falciparum calciumdependent protein kinase 1 to the parasitophorous vacuole is dependent on three N-terminal membrane anchor motifs. Mol. Microbiol., 2004, 54(3), 676-691.
99. Dvorin, J.D.; Martyn, D.C.; Patel, S.D.; Grimley, J.S.; Collins, C.R.; Hopp, C.S.; Bright, A.T.; Westenberger, S.; Winzeler, E.; Blackman, M.J.; Baker, D.A.; Wandless, T.J.; Duraisingh, M.T. A plant-like kinase in Plasmodium falciparum regulates parasite egress from erythrocytes. Science, 2010, 328(5980), 910-912.
100. Fruman, D.A.; Meyers, R.E.; Cantley, L.C. Phosphoinositide kinases. Annu. Rev. Biochem., 1998, 67, 481-507.
101. Vaid, A.; Ranjan, R.; Smythe, W.A.; Hoppe, H.C.; Sharma, P. PfPI3K, a phosphatidylinositol-3 kinase from Plasmodium falciparum, is exported to the host erythrocyte and is involved in hemoglobin trafficking. Blood, 2010, 115(12), 2500-2507.
102. McIntosh, M.T.; Vaid, A.; Hosgood, H.D.; Vijay, J.; Bhattacharya, A.; Sahani, M.H.; Baevova, P.; Joiner, K.A.; Sharma, P. Traffic to the malaria parasite food vacuole: a novel pathway involving a phosphatidylinositol 3-phosphate-binding protein. J. Biol. Chem., 2007, 282(15), 11499-11508.
103. Martin, S.K.; Jett, M.; Schneider, I. Correlation of phosphoinositide hydrolysis with exflagellation in the malaria microgametocyte. J. Parasitol., 1994, 80(3), 371-378.
104. Brown, J.R.; Auger, K.R. Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery. BMC Evol. Biol., 2011, 11(4).
105. Cai, H.; Sanchez, M.; Wang, Y.; Gu, J. In: International Joint Conference on Bioinformatics, Systems Biology and Intelligent Computing, Shanghai, PRC, Aug 03-05, 2009; IEEE Computer Soc, Conf Publish Serv, 2009; pp. 230-236.
106. Tawk, L.; Chicanne, G.; Dubremetz, J.F.; Richard, V.; Payrastre, B.; Vial, H.J.; Roy, C.; Wengelnik, K. Phosphatidylinositol 3-phosphate, an essential lipid in Plasmodium, localizes to the food vacuole membrane and the apicoplast. Eukaryot. Cell, 2010, 9(10), 1519-1530.
107. Kruger, T.; Sanchez, C.P.; Lanzer, M. Complementation of Saccharomyces cerevisiaepik1ts by a phosphatidylinositol 4-kinase from Plasmodium falciparum. Mol. Biochem. Parasitol., 2010, 172(2), 149-151.
108. Leber, W.; Skippen, A.; Fivelman, Q.L.; Bowyer, P.W.; Cockcroft, S.; Baker, D.A. A unique phosphatidylinositol 4-phosphate 5-kinase is activated by ADP-ribosylation factor in Plasmodium falciparum. Int. J. Parasitol., 2009, 39(6), 645-653.
109. Hanks, S.K.; Hunter, T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J., 1995, 9(8), 576-596.
110. Pearce, L.R.; Komander, D.; Alessi, D.R. The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol., 2010, 11(1), 9-22.
111. Tasken, K.; Aandahl, E.M. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol. Rev., 2004, 84(1), 137-167.
112. Naviglio, S.; Caraglia, M.; Abbruzzese, A.; Chiosi, E.; Di Gesto, D.; Marra, M.; Romano, M.; Sorrentino, A.; Sorvillo, L.; Spina, A.; Illiano, G. Protein kinase A as a biological target in cancer therapy. Expert Opin. Ther. Targets, 2009, 13(1), 83-92.
113. Enns, L.C.; Ladiges, W. Protein kinase A signaling as an anti-aging target. Ageing Res. Rev., 2010, 9(3), 269-272.
114. Murray, A.J. Pharmacological PKA inhibition: all may not be what it seems. Sci. Signal, 2008, 1(22), re4.
115. Li, J.; Cox, L.S. Isolation and characterisation of a cAMPdependent protein kinase catalytic subunit gene from Plasmodium falciparum. Mol. Biochem. Parasitol., 2000, 109(2), 157-163.
116. Syin, C.; Parzy, D.; Traincard, F.; Boccaccio, I.; Joshi, M.B.; Lin, D.T.; Yang, X.M.; Assemat, K.; Doerig, C.; Langsley, G. The H89 cAMP-dependent protein kinase inhibitor blocks Plasmodium falciparum development in infected erythrocytes. Eur. J. Biochem., 2001, 268(18), 4842-4849.
117. Sudo, A.; Kato, K.; Kobayashi, K.; Tohya, Y.; Akashi, H. Susceptibility of Plasmodium falciparum cyclic AMP-dependent protein kinase and its mammalian homologue to the inhibitors. Mol. Biochem. Parasitol., 2008, 160(2), 138-142.
118. Merckx, A.; Nivez, M.P.; Bouyer, G.; Alano, P.; Langsley, G.; Deitsch, K.; Thomas, S.; Doerig, C.; Egee, S. Plasmodium falciparum regulatory subunit of cAMP-dependent PKA and anion channel conductance. PLoS Pathog., 2008, 4(2), e19.
119. Yuasa, K.; Mi-Ichi, F.; Kobayashi, T.; Yamanouchi, M.; Kotera, J.; Kita, K.; Omori, K. PfPDE1, a novel cGMP-specific phosphodiesterase from the human malaria parasite Plasmodium falciparum. Biochem. J., 2005, 392(Pt 1), 221-229.
120. Wentzinger, L.; Bopp, S.; Tenor, H.; Klar, J.; Brun, R.; Beck, H.P.; Seebeck, T. Cyclic nucleotide-specific phosphodiesterases of Plasmodium falciparum: PfPDEalpha, a non-essential cGMPspecific PDE that is an integral membrane protein. Int. J. Parasitol., 2008, 38(14), 1625-1637.
121. Wurtz, N.; Chapus, C.; Desplans, J.; Parzy, D. cAMP-dependent protein kinase from Plasmodium falciparum: an update. Parasitology, 2011, 138(1), 1-25.
122. Gazarini, M.L.; Beraldo, F.H.; Almeida, F.M.; Bootman, M.; Da Silva, A.M.; Garcia, C.R. Melatonin triggers PKA activation in the rodent malaria parasite Plasmodium chabaudi. J. Pineal. Res., 2011, 50(1), 64-70.
123. Saraiva, V.B.; de Souza Silva, L.; Ferreira-DaSilva, C.T.; da Silva-Filho, J.L.; Teixeira-Ferreira, A.; Perales, J.; Souza, M.C.; Henriques, M.G.; Caruso-Neves, C.; de Sa Pinheiro, A.A. Impairment of the Plasmodium falciparum erythrocytic cycle induced by angiotensin peptides. PLoS One, 2011, 6(2), e17174.
124. Harrison, T.; Samuel, B.U.; Akompong, T.; Hamm, H.; Mohandas, N.; Lomasney, J.W.; Haldar, K. Erythrocyte G protein-coupled receptor signaling in malarial infection. Science, 2003, 301(5640), 1734-1736.
125. Murphy, S.C.; Harrison, T.; Hamm, H.E.; Lomasney, J.W.; Mohandas, N.; Haldar, K. Erythrocyte G protein as a novel target for malarial chemotherapy. PLoS Med., 2006, 3(12), e528.
126. Alessi, D.R.; James, S.R.; Downes, C.P.; Holmes, A.B.; Gaffney, P.R.; Reese, C.B.; Cohen, P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol., 1997, 7(4), 261-269.
127. Stephens, L.; Anderson, K.; Stokoe, D.; Erdjument-Bromage, H.; Painter, G.F.; Holmes, A.B.; Gaffney, P.R.; Reese, C.B.; McCormick, F.; Tempst, P.; Coadwell, J.; Hawkins, P.T. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science, 1998, 279(5351), 710-714.
128. Alessi, D.R.; Andjelkovic, M.; Caudwell, B.; Cron, P.; Morrice, N.; Cohen, P.; Hemmings, B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J., 1996, 15(23), 6541-6551.
129. Andjelkovic, M.; Alessi, D.R.; Meier, R.; Fernandez, A.; Lamb, N.J.; Frech, M.; Cron, P.; Cohen, P.; Lucocq, J.M.; Hemmings, B.A. Role of translocation in the activation and function of protein kinase B. J. Biol. Chem., 1997, 272(50), 31515-31524.
130. Vanhaesebroeck, B.; Alessi, D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J., 2000, 346 (Pt 3), 561-576.
131. Lawlor, M.A.; Alessi, D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J. Cell Sci., 2001, 114(Pt 16), 2903-2910.
132. Kumar, A.; Vaid, A.; Syin, C.; Sharma, P., PfPKB, a novel protein kinase B-like enzyme from Plasmodium falciparum -I. Identification, characterization, and possible role in parasite development. J. Biol. Chem., 2004, 279(23), 24255-24264.
133. Vaid, A.; Sharma, P. PfPKB, a protein kinase B-like enzyme from Plasmodium falciparum II. Identification of calcium/calmodulin as its upstream activator and dissection of a novel signaling pathway. J. Biol. Chem., 2006, 281(37), 27126-27133.
134. Matsumoto, Y.; Perry, G.; Scheibel, L.W.; Aikawa, M. Role of calmodulin in Plasmodium falciparum: implications for erythrocyte invasion by the merozoite. Eur. J. Cell Biol., 1987, 45(1), 36-43.
135. Garcia, C.R. Calcium homeostasis and signaling in the blood-stage malaria parasite. Parasitol. Today, 1999, 15(12), 488-491.
136. +/Calmodulin-PfPKB signaling pathway in erythrocyte invasion by Plasmodium falciparum. J. Biol. Chem., 2008, 283(9), 5589-5597.
137. Tal-Gan, Y.; Hurevich, M.; Klein, S.; Ben-Shimon, A.; Rosenthal, D.; Hazan, C.; Shalev, D.E.; Niv, M.Y.; Levitzki, A.; Gilon, C. Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt). J. Med. Chem., 2011, 54(14), 5154-5164.
138. Kuo, J.F.; Greengard, P. Cyclic nucleotide-dependent protein kinases. VI. Isolation and partial purification of a protein kinase activated by guanosine 3',5'-monophosphate. J. Biol. Chem., 1970, 245(10), 2493-2498.
139. Schlossmann, J.; Hofmann, F. cGMP-dependent protein kinases in drug discovery. Drug Discov. Today, 2005, 10(9), 627-634.
140. Deng, W.; Baker, D.A. A novel cyclic GMP-dependent protein kinase is expressed in the ring stage of the Plasmodium falciparum life cycle. Mol. Microbiol., 2002, 44(5), 1141-1151.
141. Gurnett, A.M.; Liberator, P.A.; Dulski, P.M.; Salowe, S.P.; Donald, R.G.; Anderson, J.W.; Wiltsie, J.; Diaz, C.A.; Harris, G.; Chang, B.; Darkin-Rattray, S.J.; Nare, B.; Crumley, T.; Blum, P.S.; Misura, A.S.; Tamas, T.; Sardana, M.K.; Yuan, J.; Biftu, T.; Schmatz, D.M. Purification and molecular characterization of cGMP-dependent protein kinase from Apicomplexan parasites. A novel chemotherapeutic target. J. Biol. Chem., 2002, 277(18), 15913-15922.
142. Deng, W.; Parbhu-Patel, A.; Meyer, D.J.; Baker, D.A. The role of two novel regulatory sites in the activation of the cGMP-dependent protein kinase from Plasmodium falciparum. Biochem J., 2003, 374(Pt 2), 559-565.
143. Donald, R.G.; Liberator, P.A. Molecular characterization of a coccidian parasite cGMP dependent protein kinase. Mol. Biochem. Parasitol., 2002, 120(2), 165-175.
144. Diaz, C.A.; Allocco, J.; Powles, M.A.; Yeung, L.; Donald, R.G.; Anderson, J.W.; Liberator, P.A. Characterization of Plasmodium falciparum cGMP-dependent protein kinase (PfPKG): antiparasitic activity of a PKG inhibitor. Mol. Biochem. Parasitol., 2006, 146(1), 78-88.
145. Taylor, H.M.; McRobert, L.; Grainger, M.; Sicard, A.; Dluzewski, A.R.; Hopp, C.S.; Holder, A.A.; Baker, D.A. The malaria parasite cyclic GMP-dependent protein kinase plays a central role in bloodstage schizogony. Eukaryot. Cell, 2010, 9(1), 37-45.
146. McRobert, L.; Taylor, C.J.; Deng, W.; Fivelman, Q.L.; Cummings, R.M.; Polley, S.D.; Billker, O.; Baker, D.A. Gametogenesis in malaria parasites is mediated by the cGMP-dependent protein kinase. PLoS Biol., 2008, 6(6), e139.
147. Nare, B.; Allocco, J.J.; Liberator, P.A.; Donald, R.G. Evaluation of a cyclic GMP-dependent protein kinase inhibitor in treatment of murine toxoplasmosis: gamma interferon is required for efficacy. Antimicrob. Agents Chemother., 2002, 46(2), 300-307.
148. Williams, R.B. A compartmentalised model for the estimation of the cost of coccidiosis to the world's chicken production industry. Int. J. Parasitol., 1999, 29(8), 1209-1229.
149. Donald, R.G.; Zhong, T.; Wiersma, H.; Nare, B.; Yao, D.; Lee, A.; Allocco, J.; Liberator, P.A. Anticoccidial kinase inhibitors: identification of protein kinase targets secondary to cGMPdependent protein kinase. Mol. Biochem. Parasitol., 2006, 149(1), 86-98.
150. Panchal, D.; Bhanot, P. Activity of a trisubstituted pyrrole in inhibiting sporozoite invasion and blocking malaria infection. Antimicrob. Agents Chemother., 2010, 54(10), 4269-4274.
151. Doerig, C.M.; Parzy, D.; Langsley, G.; Horrocks, P.; Carter, R.; Doerig, C.D. A MAP kinase homologue from the human malaria parasite, Plasmodium falciparum. Gene, 1996, 177(1-2), 1-6.
152. Lin, D.T.; Goldman, N.D.; Syin, C. Stage-specific expression of a Plasmodium falciparum protein related to the eukaryotic mitogenactivated protein kinases. Mol. Biochem. Parasitol., 1996, 78(1-2), 67-77.
153. Graeser, R.; Kury, P.; Franklin, R.M.; Kappes, B. Characterization of a mitogen-activated protein (MAP) kinase from Plasmodium falciparum. Mol. Microbiol., 1997, 23(1), 151-159.
154. Dorin, D.; Alano, P.; Boccaccio, I.; Ciceron, L.; Doerig, C.; Sulpice, R.; Parzy, D. An atypical mitogen-activated protein kinase (MAPK) homologue expressed in gametocytes of the human malaria parasite Plasmodium falciparum. Identification of a MAPK signature. J. Biol. Chem., 1999, 274(42), 29912-29920.
155. Tewari, R.; Dorin, D.; Moon, R.; Doerig, C.; Billker, O. An atypical mitogen-activated protein kinase controls cytokinesis and flagellar motility during male gamete formation in a malaria parasite. Mol. Microbiol., 2005, 58(5), 1253-1263.
156. Dorin-Semblat, D.; Quashie, N.; Halbert, J.; Sicard, A.; Doerig, C.; Peat, E.; Ranford-Cartwright, L. Functional characterization of both MAP kinases of the human malaria parasite Plasmodium falciparum by reverse genetics. Mol. Microbiol., 2007, 65(5), 1170-1180.
157. Khan, S.M.; Franke-Fayard, B.; Mair, G.R.; Lasonder, E.; Janse, C.J.; Mann, M.; Waters, A.P. Proteome analysis of separated male and female gametocytes reveals novel sex-specific Plasmodium biology. Cell, 2005, 121(5), 675-687.
158. Rangarajan, R.; Bei, A.K.; Jethwaney, D.; Maldonado, P.; Dorin, D.; Sultan, A.A.; Doerig, C. A mitogen-activated protein kinase regulates male gametogenesis and transmission of the malaria parasite Plasmodium berghei. EMBO Rep., 2005, 6(5), 464-469.
159. Brumlik, M.J.; Pandeswara, S.; Ludwig, S.M.; Murthy, K.; Curiel, T.J. Parasite mitogen-activated protein kinases as drug discovery targets to treat human protozoan pathogens. J. Signal Transduct., 2011, 2011(971-968).
160. Brumlik, M.J.; Nkhoma, S.; Kious, M.J.; Thompson, G.R., 3rd; Patterson, T.F.; Siekierka, J.J.; Anderson, T.J.; Curiel, T.J. Human p38 mitogen-activated protein kinase inhibitor drugs inhibit Plasmodium falciparum replication. Exp Parasitol, 2011, 128(2), 170-175.
161. Zhou, T.J.; Raman, M.; Gao, Y.; Earnest, S.; Chen, Z.; Machius, M.; Cobb, M.H.; Goldsmith, E.J. Crystal structure of the TAO2 kinase domain: Activation and specificity of a Ste20p MAP3K. Structure, 2004, 12(10), 1891-1900.
162. Dorin-Semblat, D.; Sicard, A.; Doerig, C.; Ranford-Cartwright, L. Disruption of the PfPK7 gene impairs schizogony and sporogony in the human malaria parasite Plasmodium falciparum. Eukaryot. Cell, 2008, 7(2), 279-285.
163. Bouloc, N.; Large, J.M.; Smiljanic, E.; Whalley, D.; Ansell, K.H.; Edlin, C.D.; Bryans, J.S. Synthesis and in vitro evaluation of imidazopyridazines as novel inhibitors of the malarial kinase PfPK7. Bioorg. Med. Chem. Lett., 2008, 18(19), 5294-5298.
164. Madhavan, T.; Kothandan, G.; Gadhe, C.G.; Cho, S.J. QSAR analysis on PfPK7 inhibitors using HQSAR, CoMFA, and CoMSIA. Med. Chem. Res., 2011. DOI: 10.1007/s00044-011-9572-x.
165. Embi, N.; Rylatt, D.B.; Cohen, P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem., 1980, 107(2), 519-527.
166. Kockeritz, L.; Doble, B.; Patel, S.; Woodgett, J.R. Glycogen synthase kinase-3--an overview of an over-achieving protein kinase. Curr. Drug Targets, 2006, 7(11), 1377-1388.
167. Frame, S.; Cohen, P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J., 2001, 359(Pt 1), 1-16.
168. Droucheau, E.; Primot, A.; Thomas, V.; Mattei, D.; Knockaert, M.; Richardson, C.; Sallicandro, P.; Alano, P.; Jafarshad, A.; Baratte, B.; Kunick, C.; Parzy, D.; Pearl, L.; Doerig, C.; Meijer, L. Plasmodium falciparum glycogen synthase kinase-3: molecular model, expression, intracellular localisation and selective inhibitors. Biochim. Biophys. Acta., 2004, 1697(1-2), 181-196.
169. Kruggel, S.; Lemcke, T. Generation and evaluation of a homology model of PfGSK-3. Arch. Pharm. (Weinheim), 2009, 342(6), 327-332.
170. Osolodkin, D.I.; Zakharevich, N.V.; Palyulin, V.A.; Danilenko, V.N.; Zefirov, N.S. Bioinformatic analysis of glycogen synthase kinase 3: human versus parasite kinases. Parasitology, 2011, 138(6), 1-11.
171. Oduor, R.O.; Ojo, K.K.; Williams, G.P.; Bertelli, F.; Mills, J.; Maes, L.; Pryde, D.C.; Parkinson, T.; Van Voorhis, W.C.; Holler, T.P. Trypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: a public-private partnership to identify novel leads. PLoS Negl. Trop. Dis., 2011, 5(4), e1017.
172. Nurul Aiezzah, Z.; Noor, E.; Hasidah, M.S. Suppression of Plasmodium berghei parasitemia by LiCl in an animal infection model. Trop. Biomed., 2010, 27(3), 624-631.
173. Peng, J.; Kudrimoti, S.; Prasanna, S.; Odde, S.; Doerksen, R.J.; Pennaka, H.K.; Choo, Y.M.; Rao, K.V.; Tekwani, B.L.; Madgula, V.; Khan, S.I.; Wang, B.; Mayer, A.M.; Jacob, M.R.; Tu, L.C.; Gertsch, J.; Hamann, M.T. Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections. J. Med. Chem., 2010, 53(1), 61-76.
174. Witkowski, B.; Lelievre, J.; Barragan, M.J.L.; Laurent, V.; Su, X.Z.; Berry, A.; Benoit-Vical, F. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob. Agents Chemother., 2010, 54(5), 1872-1877.
175. Dixit, A.; Singh, P.K.; Sharma, G.P.; Malhotra, P.; Sharma, P. PfSRPK1, a Novel splicing-related kinase from Plasmodium falciparum. J. Biol. Chem., 2010, 285(49), 38315-38323.
176. Bhattacharjee, A.K.; Geyer, J.A.; Woodard, C.L.; Kathcart, A.K.; Nichols, D.A.; Prigge, S.T.; Li, Z.; Mott, B.T.; Waters, N.C. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors. J. Med. Chem., 2004, 47(22), 5418-5426.
177. Zhao, Y.; Pokutta, S.; Maurer, P.; Lindt, M.; Franklin, R.M.; Kappes, B. Calcium-binding properties of a calcium-dependent protein kinase from Plasmodium falciparum and the significance of individual calcium-binding sites for kinase activation. Biochemistry, 1994, 33(12), 3714-3721.
178. Zhao, Y.; Franklin, R.M.; Kappes, B. Plasmodium falciparum calcium-dependent protein kinase phosphorylates proteins of the host erythrocytic membrane. Mol. Biochem. Parasitol., 1994, 66(2), 329-343.
179. Lemercier, G.; Fernandez-Montalvan, A.; Shaw, J.P.; Kugelstadt, D.; Bomke, J.; Domostoj, M.; Schwarz, M.K.; Scheer, A.; Kappes, B.; Leroy, D. Identification and characterization of novel small molecules as potent inhibitors of the plasmodial calcium-dependent protein kinase 1. Biochemistry, 2009, 48(27), 6379-6389.